HICON- sodium iodide i 131 solution

HICON by

Drug Labeling and Warnings

HICON by is a Prescription medication manufactured, distributed, or labeled by Jubilant DraxImage Inc., dba Jubilant Radiopharma. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    HICON® is indicated for the treatment of hyperthyroidism and selected cases of thyroid carcinoma.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Radiation Safety

    • HICON® is a radioactive drug. Handle with appropriate safety measures to minimize radiation exposure to the patient and healthcare workers [see Warnings and Precautions (5.7)]:
      • Use only by, or under the direction of, physicians who are qualified by specific training and experience in the safe use and handling of radioactive materials, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.
      • Use waterproof gloves when handling and administering the product.
      • Maintain adequate shielding during the life of the product.
      • Measure patient dose with a suitable radioactivity calibration system immediately prior to administration.

    2.2 Important Administration Instructions

    • Do not directly administer the concentrated sodium iodide I 131 solution provided with HICON® to patients. The concentrated sodium iodide I 131 solution must be diluted and prepared prior to administration [see Dosage and Administration (2.4)].
    • Obtain a pregnancy test in females of reproductive potential prior to administration to verify the absence of pregnancy [see Contraindications (4) andUse in Specific Populations (8.1,8.3)].
    • Instruct patients to fast at least 2 hours before and 2 hours after administration to ensure absorption.
    • Instruct patients to hydrate before and after administration of sodium iodide I 131 and to void frequently to enhance urinary elimination of the radioiodide that is not absorbed by the thyroid gland [see Warnings and Precautions (5.2)].
    • Instruct patients to maintain a low-iodide diet two weeks prior to radioiodide administration and continue for several days during the uptake or imaging process [see Warnings and Precautions (5.8) and Drug Interactions (7)].
    • Instruct patients to discontinue the anti-thyroid therapy three days before administration of sodium iodide I 131 [see Warnings and Precautions (5.8) and Drug Interactions (7)].
    • For patients with a history of renal impairment, evaluate renal function for therapeutic planning and consider dosimetry [see Use in Specific Populations (8.6)].
    • Obtain a complete blood count within one month of therapy. If patients show leukopenia or thrombocytopenia, dosimetry should be used to determine a safe sodium iodide I 131 activity, while delivering less than 2 Gy to the bone marrow [see Warnings and Precautions (5.2)].

    2.3 Recommended Dosage and Administration

    Individualization of Therapy
    The recommended dose for orally administered sodium iodide I 131 capsules or solution is based on the thyroid gland uptake as well as the size of the gland. Thyroidal uptake and size should be determined by the physician prior to treatment and may be useful in calculating the therapeutic dose to be administered to the individual patient.

    Treatment of Hyperthyroidism
    The recommended dose is 148 to 370 MBq (4 to 10 mCi) administered orally. Toxic nodular goiter may require a larger dose.

    Treatment of Thyroid Carcinoma
    The recommended dose is 1100 to 3700 MBq (30 to 100 mCi) administered orally. For subsequent ablation of metastases, the recommended dose is 3700 to 7400 MBq (100 to 200 mCi) administered orally.

    2.4 Dilution and Preparation Instructions

    Preparation of Dilute Sodium Iodide I 131 Solution USP

    1. Using the calibration date and radionuclidic concentration on the label of the product vial, calculate the required volume to produce the necessary dose in MBq or mCi.
    2. Using a shielded syringe, remove the required volume.
    3. Using the shielded syringe, transfer the required volume to a suitably shielded receiving vial.
    4. Add diluent solution to the receiving vial to produce a final dose of the desired volume.
    5. The recommended diluent is Purified Water containing 0.2 % sodium thiosulfate as a reducing agent. Acidic diluents should not be used as they may cause the pH to drop below 7.5 and stimulate the volatilization of Iodine I-131 hydriodic acid.
    6. Present the dose in a shielded container for administration to the patient with a straw

    Preparation of Sodium Iodide I 131 Capsules USP

    1. HICON® includes one large gelatin capsule and one small gelatin capsule for each dose prepared. Each large capsule is empty and each small capsule contains approximately 300 mg of dibasic sodium phosphate anhydrous as the absorbing buffer.
    2. Using the calibration date and radionuclidic concentration on the label of the product vial, calculate the required volume to produce the necessary dose in MBq or mCi.
    3. Open one large capsule supplied with HICON® by pulling apart the capsule into two pieces as illustrated below:
      image description
    4. Insert an unopened small capsule supplied with HICON® into the bottom half of the empty large capsule as illustrated below:
      image description
    5. With an appropriate syringe, withdraw the required volume of sodium iodide I 131 Solution USP (maximum 150 microliters) from the vial as illustrated below:
      image description
    6. Inject into the center of the small capsule through the top as illustrated below:
      image description
    7. Slip the upper half of the large capsule over the bottom half to completely cover the small capsule and push down gently until locked as illustrated below:
      image description
    8. Measure the patient dose in a suitable radioactivity calibration system immediately prior to administration.
    9. Prepared capsules may be stored in a suitable polypropylene container and place inside a lead pot until use, within seven days.

    2.5 Radiation Dosimetry

    • The biokinetic modeling and radiation dose distributions associated with thyroid uptake of iodide I 131 depend on dietary intake of stable iodide and presume normal production of thyroid hormone. Table 1 shows a range of uptake percentages in an average adult (73.7 kg reference model). Table 1 is not intended to be used for treatment planning.
    • For a thyroid blocked from iodide uptake in the production of hormones, the effective half-life of iodide I 131 is approximately 1.4 hours; for "low" to "high" uptake, the effective half-life of I 131 ranges from approximately 80 to 90 hours.
    Table 1*
  • * Table 1 is not intended for treatment planning.
  • † These columns are not applicable to estimate organ or effective doses in patients following thyroidectomy. In patients with thyroid cancer following thyroidectomy, organ and effective doses can be estimated from the "blocked"-thyroid-uptake values.
  • ‡ These values presume unimpeded production of thyroid hormone and may not be applicable to estimate thyroid dose and effective dose in patients who have had previous treatment with I 131 for hyperthyroidism
    		•
    Absorbed dose per unit activity sodium iodide I 131 administered orally (mGy/MBq) in adult (73.7-kg reference model)
     OrganThyroid uptake of I 131 (% administered activity A0)
    24 h after oral administration

     Blocked thyroid
    (0% A0)

     Low uptake†
    (16% A0)

     Medium uptake†
    (26% A0)

     High uptake†
    (36% A0)
     Adrenals 0.044 0.051 0.055 0.059
     Bone surfaces

     0.030

    		 0.089 0.12 0.16
     Brain 0.021 0.093 0.13 0.17
     Breast0.020 0.038 0.048 0.058
     Gallbladder wall0.037 0.043 0.046 0.049
    Gastrointestinal tract
     Esophagus0.024 0.10 0.14 0.19
     Stomach wall0.87 0.77 0.71 0.66
     Small intestine wall0.035 0.033 0.032 0.032
     Colon wall0.14 0.14 0.14 0.14
     (Upper large intestine wall)0.12 0.12 0.12 0.12
     (Lower large intestine wall) 0.17 0.17 0.17 0.16
     Heart wall 0.062 0.089 0.10 0.12
     Kidneys 0.27 0.27 0.27 0.27
     Liver 0.050 0.093 0.12 0.14
     Lungs 0.053 0.10 0.13 0.15
     Muscles 0.026 0.084 0.12 0.15
     Ovaries 0.038 0.037 0.036 0.035
     Pancreas 0.060 0.064 0.066 0.068
     Red marrow 0.031 0.072 0.095 0.12
     Salivary glands 0.27 0.22 0.19 0.16
     Skin 0.019 0.043 0.057 0.071
     Spleen 0.064 0.069 0.072 0.075
     Testes 0.025 0.024 0.023 0.22
     Thymus 0.024 0.10 0.14 0.19
     Thyroid 2.2 280‡ 430‡ 580‡
     Urinary bladder wall 0.54 0.45 0.39 0.34
     Uterus 0.045 0.042 0.040 0.038
     Remaining organs 0.029 0.084 0.11 0.15
     Effective dose per administered activity (mSv/MBq) 0.28 14‡ 22‡ 29‡

  • 3 DOSAGE FORMS AND STRENGTHS

    HICON® is available in 1 mL size, clear vials containing a colorless, aqueous, concentrated Sodium Iodide I 131 Solution [9,250 MBq, 18,500 MBq, and 37,000 MBq at time of calibration] for the preparation of sodium iodide I 131 capsules, therapeutic or sodium iodide I 131 solution, therapeutic. Refer to Table 2 for the radioactivity and volume in each vial. Large gelatin capsules (empty) and small gelatin capsules containing approximately 300 mg of dibasic sodium phosphate anhydrous as the absorbing buffer are supplied along with HICON® for the preparation of sodium iodide I 131 capsules, therapeutic.

    Table 2 HICON® Concentrated Sodium Iodide I 131 Solution
    *At time of calibration.

     Total Radioactivity/Vial
    MBq

     Solution Volume
    (mL)/Vial
     9,250 (250 mCi) 0.25
     18,500 (500 mCi) 0.5
     37,000 (1000 mCi) 1

  • 4 CONTRAINDICATIONS

    HICON® is contraindicated in:

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Radiation-induced Thyroiditis

    Sodium iodide I 131 may cause thyroiditis with release of thyroid hormone, which may aggravate hyperthyroidism and thyrotoxic cardiac disease [see Adverse Reactions (6)]. When treating hyperthyroidism, consider pre-treatment anti-thyroid medication to help deplete the thyroid hormone. Discontinue the anti-thyroid therapy three days before administration of sodium iodide I 131 [see Drug Interactions (7)]. Consider a beta-blocker pre or post-treatment to minimize the risk of hyperthyroidism and thyroid storm.

    The thyroiditis may cause gland enlargement resulting in tenderness and swelling of the neck, pain on swallowing, sore throat, and cough; which may occur approximately the third day after sodium iodide I 131 administration. Consider management with pain-reliever or anti-inflammatory medications.

    5.2 Radiation-induced Toxicities

    Sodium Iodide I 131 may cause radiation induced toxicities [see Adverse Reactions (6)]:

    • Dose-dependent fatalities (bone marrow suppression, malignancy).
    • Dose-dependent hematopoietic suppression which manifests as a transient thrombocytopenia or neutropenia 3-5 weeks following sodium iodide I 131 administrations, may lead to increased susceptibility to infections or bleeding.
    • Salivary gland toxicity: sialadenitis, xerostomia.
    • Lacrimal gland toxicity: conjunctivitis, xerophthalmia, and epiphora.

    Obtain a complete blood count within one month of therapy. If patients show leukopenia or thrombocytopenia, dosimetry should be used to determine a safe sodium iodide I 131 activity, while delivering less than 2 Gy to the bone marrow.

    Advise good hydration for one week following sodium iodide I 131 administration and stimulate salivary flow via a sialagogue (e.g. sugar-free candy or gum, pilocarpine, and ascorbic acid) to reduce radiation exposure to the salivary glands.

    Advise patients to void frequently after administration of radioiodide to enhance excretion.

    5.3 Hypersensitivity Reactions

    Hypersensitivity reactions including anaphylaxis may occur in patients who receive sodium iodide I 131. Although iodide is not considered an allergen, hypersensitivity reactions may occur in relation with excipients or chemical component of the capsule, such as sodium thiosulfate. Obtain and document an allergy history, particularly a sulfite allergy. Emergency resuscitation equipment and personnel should be immediately available [see Adverse Reactions (6)].

    5.4 Fetal Toxicity

    HICON® is contraindicated in pregnancy because sodium iodide I 131 crosses the placenta and fetal exposure can lead to neonatal hypothyroidism. Multiple reports in the published literature describe hypothyroidism in the neonates following in utero exposure to sodium iodide I 131. Some cases of neonatal hypothyroidism were severe and irreversible. Verify pregnancy status of females of reproductive potential prior to initiating HICON® treatment. Advise females and males of reproductive potential to use effective contraception during treatment with HICON® and for at least six months after the last dose [see Use in Specific Populations (8.1, 8.3)].

    5.5 Increased Radiation Exposure to Breast Tissue with Lactation

    HICON® is contraindicated in lactating women because sodium iodide I 131 concentrates in the breast via the increased expression of the sodium iodide symporter in breast tissue with lactation. The literature describes moderate to marked radioiodine uptake in the breast tissue for 5-32 weeks post cessation of breast feeding. Advise lactating women to discontinue breast feeding at least 6 weeks prior to administration of sodium iodide I 131 to allow sufficient time for involution to occur and to avoid excess concentration of sodium iodide I 131 in breast tissue. Consider administration of drugs to suppress lactation. Consider diagnostic scintigraphy before administration of sodium iodide I 131 to assess the persistence of uptake by breast tissue. If sodium iodide I 131 is administered in the postpartum period, the lactating mother should not breastfeed the infant [see Use in Specific Populations (8.2)].

    5.6 Transient Infertility

    Transient dose-related impairment of testicular function in men and transient ovarian insufficiency in women has been reported after sodium iodide I 131 therapy. Consider sperm banking for men who are anticipated to receive cumulative sodium iodide I 131 doses greater than 19,000 MBq (520 mCi) [see Use in Specific Populations (8.3)].

    5.7 Risk of Radiation Exposure

    Household Contacts
    Instruct patients to follow radiation safety precautions after receiving HICON® to minimize the radiation contamination of other persons or the environment. Patients should avoid close contact with others, especially pregnant women and children, and take care to avoid contamination of other persons or the environment with body fluids.

    Patients and Healthcare Providers
    HICON® contributes to a patient’s overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Follow safe handling and administration to minimize radiation exposure to the patient and healthcare providers.

    5.8 Risk of Decreased Effectiveness of Therapy

    Certain food or drugs may alter the thyroid uptake of sodium iodide I 131 and diminish its effectiveness. Recent intake of stable iodide in any form, or the use of thyroid or anti-thyroid drugs may diminish thyroid uptake of sodium iodide I 131 [see Drug Interactions (7)].

  • 6 ADVERSE REACTIONS

    The following serious adverse reactions are described below and elsewhere in labeling:

    The following adverse reactions have been identified during post-approval use of sodium iodide I 131. Because these reactions are voluntarily reported by from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    • Gastrointestinal disorders: sialadenitis, salivary gland dysfunction, nausea, vomiting, gastritis.
    • Cardiac disorders: chest pain, tachycardia.
    • Skin and subcutaneous tissue disorders: itching, rash, hives.
    • Endocrine disorders: hypothyroidism, hyperthyroidism, thyrotoxic crisis, hypoparathyroidism
    • General disorders and administration site conditions: local swelling of thyroid or sites of iodide avid tumor.
    • Hematologic and lymphatic disorders including fatalities: bone marrow depression, anemia, leukopenia, thrombocytopenia, and blood dyscrasia.
    • Neoplasms benign, malignant and unspecified (including cysts and polyps): acute leukemia, solid cancer.
    • Eye disorders: lacrimal gland dysfunction.
    • Congenital, familial and genetic disorders: congenital hypothyroidism, chromosomal abnormalities.
    • Immune system disorders: bronchospasm.
    • Nervous system disorders: headache, *cerebral edema.
    • Respiratory, thoracic and mediastinal disorders: **radiation pneumonitis, **pulmonary fibrosis.

    * In patients with iodide-avid brain metastases
    ** In patients with iodide-avid lung metastases

  • 7 DRUG INTERACTIONS

    • Concomitant use of bone marrow depressants may enhance the depression of the hematopoietic system caused by the use of large doses of sodium iodide I 131 [see Warnings and Precautions (5.2)].
    • Many drugs and iodide-containing foods interfere with the accumulation of radioiodide by the thyroid. Review the patients history, current medications, and recent diagnostic tests prior to the administration of sodium iodide I 131 [see Warnings and Precautions (5.8)].
    • Advise patients to maintain a low-iodide diet two weeks prior to radioiodide administration and continue for several days during the uptake or imaging process and to discontinue taking the following products before they undergo the procedure as shown in Table 3.
    Table 3 Pharmaceuticals/OTCs/Agents Blocking Radioiodine Uptake
     Type of Medication Recommended time of withdrawal
     Thionamide medications
     (e.g., propylthiouracil, methimazole, carbimazole)    		  3 days
     Multivitamins containing iodide  10 days
    Natural or synthetic thyroid hormones
     triiodothyronine
     thyroxine

      2 weeks

      4 weeks
     Iodide-containing foods: iodized salt, dairy products, egg yolks, seafood, turkey and liver  2 weeks
     Kelp, agar, carrageenan, Lugol solution  3 weeks
     Saturated solution of potassium iodide  3 weeks
     Topical iodide
     (e.g., surgical skin preparation)    		  3 weeks
    Intravenous radiographic contrast agents
       Water soluble
       Lipophilic

      2 months

      6 months
     Amiodarone  6 months

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary
    HICON® is contraindicated in pregnancy because fetal exposure can lead to neonatal hypothyroidism, which in some cases is severe and irreversible. Data from the published literature describe thyroid abnormalities after fetal exposure; including agenesis of the thyroid and hypothyroidism (see Data). No animal reproductive studies have been conducted.

    Clinical Considerations.
    Fetal/ Neonatal Adverse Reactions
    A fetus exposed to sodium iodide I 131 can develop neonatal hypothyroidism. Delay in diagnosis of neonatal hypothyroidism after exposure to sodium iodide I 131 in utero can result in severe sequelae such as decreased mental capacity and delayed bone age. Monitor thyroid function in any infant born after in utero exposure to sodium iodide I 131.

    Data
    Human Data
    Sodium iodide I 131 crosses the placenta and the fetal thyroid begins to concentrate iodide during the 10-12th week of gestation. In literature reports of maternal exposures to sodium iodide I 131 at doses of 333 – 8325 MBq (9 – 225 mCi) during 4-26 weeks gestational age, the most common adverse outcomes were hypothyroid infants and children.

    8.2 Lactation

    Risk Summary
    HICON® is contraindicated during lactation because I 131 concentrates in the breast during lactation via the increased expression of the sodium iodide symporter in breast tissue [see Warnings and Precautions (5.5)]. If sodium iodide I 131 is administered in the postpartum period, the lactating mother should not breastfeed. In addition, to minimize the absorbed radiation dose to the breast tissue, breastfeeding and breast-pumping should be discontinued for at least 6 weeks before administration of sodium iodide I 131 (see Data). Women may breast feed with the birth of another child.

    Infants exposed to sodium iodide I 131 through breast milk are at risk for development of hypothyroidism because sodium iodide I 131 is distributed into breast milk and may reach concentrations equal to or greater than concentrations in maternal plasma (see Data).

    Data
    Human Data
    Limited published literature describes sodium iodide I 131 transfer into breast milk and thyroidal uptake by the breastfed infant. The amount of sodium Iodide I 131 detected in the breast milk at 36-48 hours after administration is 1-27% of the injected dose (with injected doses between 1.1 – 5143 MBq).

    8.3 Female and Males of Reproductive Potential

    HICON® is contraindicated in pregnancy because of the risk of fetal hypothyroidism [see Use in Specific Populations (8.1)].

    Pregnancy Testing
    Obtain a pregnancy test in females of reproductive potential and verify the absence of pregnancy before initiating treatment [see Dosage and Administration (2.2), Warnings and Precautions (5.4)].

    Contraception
    Advise females and males of reproductive potential to use effective contraception during treatment with HICON® and for at least six months after the last dose of HICON®.

    Infertility
    Females
    Fertility may be impaired with HICON® treatment. Transient amenorrhea and ovarian insufficiency have been observed after sodium iodide I 131 therapy in females. The literature describes reports of transient menstrual cycle irregularities, including amenorrhea, and ovarian failure in females treated with cumulative doses of 1000 – 59,000 MBq (27 – 1594 mCi) sodium iodide I 131.

    Males
    Fertility may be impaired with HICON® treatment. Discuss sperm banking for males who are expected to receive a high cumulative dose of sodium iodide I 131. Transient dose-related impairment of testicular function after sodium iodide I 131 therapy has been reported in the published literature. The literature describes reports of males treated with sodium iodide I 131 at doses of 370 MBq – 22,000 MBq (10 – 595 mCi) resulting in transiently impaired testicular function (including spermatogenesis). Permanent impairment is described with high cumulative doses ranging from 19,000 – 29,000 MBq (520 – 800 mCi).

    8.4 Pediatric Use

    Safety and efficacy in pediatric patients have not been established. Pediatric patients are at an increased lifetime risk for malignancy from radiation exposure

    8.5 Geriatric Use

    Clinical experience has not identified differences in safety or effectiveness in geriatric patients compared to younger patients. However, elderly patients are more likely to have decreased renal function and radiation exposure is greater in patients with impaired renal function [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].

    8.6 Renal Impairment

    HICON® is primarily excreted by the kidneys. Renal function impairment decreases excretion of sodium iodide I 131 and increases the radiation exposure and risk of radiation toxicity. For patients with a history of renal impairment, evaluate renal function for therapeutic planning and consider dosimetry. Sodium Iodide I 131 is dialyzable. Hemodialysis can be used to reduce total body radiation exposure [see Clinical Pharmacology (12.3)].

  • 10 OVERDOSAGE

    In case of exposure to a radioactive dose of sodium iodide I 131 exceeding the intended therapeutic dose, provide general supportive care, promote frequent voiding, monitor for bone marrow and thyroid suppression. Consider administering a thyroid blocking agent (e.g. potassium iodide (KI) or perchlorate) promptly within 4 to 6 hours after the exposure. Assess the benefit of administering a thyroid blocking agent against the risk of failure of sodium iodide I 131 therapy. Appropriate replacement therapy is recommended if hypothyroidism occurs.

  • 11 DESCRIPTION

    HICON®, a radioactive therapeutic agent, provides a concentrated solution of sodium iodide I 131 with a radioconcentration of 37,000 MBq/mL (1,000 mCi/mL). Each mL of the concentrated solution contains 37,000 MBq of no-carrier-added sodium iodide I 131, disodium edetate dihydrate USP as a stabilizer, sodium thiosulfate pentahydrate USP as a reducing agent, and dibasic sodium phosphate anhydrous USP. The pH of the concentrated solution is between 7.5 and 10.

    The concentrated solution provided with HICON® is used for the preparation of sodium iodide I 131 capsules or sodium iodide I 131 solution of varying strengths for oral administration for therapy.

    Sodium iodide I 131 solution is designated chemically as Na 131I and has a molecular weight of 153.99. Hard gelatin capsules, provided for the preparation of the sodium iodide I 131 capsules final dosage form, contain approximately 300 mg of dibasic sodium phosphate anhydrous USP as the absorbing buffer.

    11.1 Physical Characteristics

    Iodine I-131 decays by beta emission and associated gamma emission with a physical half-life of 8.04 days. The principal radiation emissions are listed in Table 4.

    Table 4 Principal Radiation Emission Data from Decay of Sodium Iodide I 131
     RadiationMean % per
    Disintegration    		Mean Energy
    (keV)
     Beta-1 2.1% 69.4
     Beta-3 7.2% 96.6
     Beta-4 89.4% 191.6
     Gamma-7 6.1% 284.3
     Gamma-14 81.2% 364.5
     Gamma-18 7.1% 637.0

    11.2 External Radiation

    The specific gamma-ray constant for iodide I 131 is 4.26 × 10-13 C·m2·kg-1·MBq-1·s-1 (2.2 R·cm2/mCi·hr). The first half-value thickness of lead (Pb) for iodide I 131 is 0.27 cm. A range of values for the relative attenuation of the radiation emitted by iodide I 131 that results from interposition of various thicknesses of Pb is shown in Table 5. For example, the use of 2.59 cm of Pb will decrease the external radiation exposure by a factor of about 1,000.

    Table 5 Radiation Attenuation of Iodine I 131 by Lead Shielding

     Shield Thickness
    (Pb) cm

    		 Coefficient of Attenuation
     0.270.5
     0.56 0.25
     0.99 10-1
     2.59 10-2
     4.53 10-3

    To correct for physical decay of iodine I 131, the fractions that remain at selected intervals after the time of calibration are shown in Table 6.

    Table 6 Physical Decay Chart: Iodine I-131 Half-Life 8.04 days
    *Calibration time
    DaysFraction RemainingDaysFraction RemainingDaysFraction Remaining
    0*1.00011.38822.151
    1.91812.35623.138
    2.84213.32724.127
    3.77314.30025.116
    4.70915.27526.107
    5.65116.25327.098
    6.59717.23228.090
    7.54818.21329.083
    8.50319.19530.076
    9.46120.179
    10.42321.164

  • 12 CLINICAL PHARMACOLOGY


    12.1 Mechanism of Action

    Iodide is actively transported by the sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Iodide is concentrated in follicular cells to levels up to 50 times higher than in the plasma. Iodide is metabolically oxidized by thyroid peroxidase to iodinium (I+) which in turn iodinates tyrosine residues of thyroglobulin (tri or tetra-iodinated tyrosine). The beta emission of I 131 is responsible for the therapeutic effect.

    12.2 Pharmacodynamics

    The relationship between the extent of iodide I 131 exposure and pharmacologic effects has not been explored in clinical trials.

    12.3 Pharmacokinetics

    Absorption
    Following oral administration of HICON®, 90% of the administered radioactivity of Iodide I 131 is systemically absorbed in the first 60 minutes.

    Distribution
    Following absorption, I 131 is distributed within the extra-cellular space. It is actively transported by the sodium-iodide symporter (NIS) protein, and binds to thyroglobulin resulting in accumulation in the thyroid. The thyroid uptake of iodide is usually increased in hyperthyroidism and in goiter, and is decreased in hypothyroidism. Sodium Iodide I 131 also accumulates in the stomach, choroid plexus, salivary glands, breast, liver, gall bladder, and kidneys.

    Elimination
    Metabolism
    In thyroidal follicular cells iodide is oxidized through the action of thyroid peroxidase to iodinium (I+) which in turn iodinates tyrosine residues of thyroglobulin.

    Excretion
    Sodium iodide I 131 is excreted in urine and feces. The normal range of urinary excretion is 37% to 75% of the administered dose, varying with the thyroid and renal function of the patient. Fecal excretion is about 10%.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    HICON® is supplied in 1 mL clear vials that contain approximately 37,000 MBq (250 mCi), 18,500 MBq (500 mCi), and 37,000 MBq (1,000 mCi) at the time of calibration.

    HICON®
     NDCVolume of Concentrated SolutionTotal Radioactivity per Vial
     65174-880-25 0.25 mL9,250 <MBq (250 mCi)
     65174-880-50 0.50 mL18,500 MBq (500 mCi)
     65174-880-00 1 mL37,000 MBq (1,000 mCi)

    A minimum of one blister package of 10 empty large hard gelatin capsules and a minimum of one blister package of 10 small hard gelatin capsules containing approximately 300 mg of dibasic sodium phosphate anhydrous as the absorbing buffer are supplied along with HICON® for the preparation of sodium iodide I 131 capsules, therapeutic.

    16.2 Storage

    HICON® should be stored between 2°C and 25°C (36°F and 77°F). Store and dispose of HICON® in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide.

    Discard unused capsules after all HICON® solution has been dispensed or expired. New blister packages of hard gelatin capsules are provided with each new shipment of HICON®.

    This radiopharmaceutical is approved for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.

  • 17 PATIENT COUNSELING INFORMATION

    Radiation Safety Precautions [see Warnings and Precautions (5.7)].
    Review the most recent professional society guidelines and publications that describe important components of the patient counseling process and discuss measures to minimize inadvertent radiation exposure to the patient.

    Fetal Toxicity [see Contraindications (4), Warnings and Precautions (5.4) and Use in Specific Populations (8.1,8.3)].

    • Advise female patients of the risk to a fetus.
    • Advise females and males of reproductive potential to use effective contraception during treatment with HICON® and for at least 6 months after the last dose.
    • Advise female patients to contact their healthcare provider with a known or suspected pregnancy.

    Lactation
    Instruct women to stop breastfeeding and breast-pumping at least 6 weeks prior to HICON® administration [see Contraindications (4), Warnings and Precautions (5.5) and Use in Specific Populations (8.2)].

    Effects on Fertility
    Advise females and males of reproductive potential of the potential for impaired fertility with HICON® treatment [see Warnings and Precautions (5.6) and Use in Specific Populations (8.3)].

    Manufactured by:
    Jubilant DraxImage Inc., Kirkland, Québec Canada, H9H 4J4

    Art rev.: 1.0

  • PRINCIPAL DISPLAY PANEL

    Label 1
    Label 2
    label 3
    label 4
    Label 5
    Label 6
  • INGREDIENTS AND APPEARANCE
    HICON  
    sodium iodide i 131 solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 65174-880
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SODIUM IODIDE I-131 (UNII: 29VCO8ACHH) (IODIDE ION I-131 - UNII:4GC1FOQ22U) IODIDE ION I-1311 mCi  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    Edetate Disodium (UNII: 7FLD91C86K)  
    Sodium Thiosulfate (UNII: HX1032V43M)  
    SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 65174-880-251 in 1 KIT04/07/2003
    1.25 mL in 1 VIAL; Type 0: Not a Combination Product
    2NDC: 65174-880-501 in 1 KIT04/07/2003
    2.5 mL in 1 VIAL; Type 0: Not a Combination Product
    3NDC: 65174-880-001 in 1 KIT04/07/2003
    31 mL in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02130504/07/2003
    Labeler - Jubilant DraxImage Inc. (243604761)
    Registrant - Jubilant DraxImage Inc. (243604761)
    Establishment
    NameAddressID/FEIBusiness Operations
    Jubilant DraxImage Inc.243604761MANUFACTURE(65174-880)

    • Trademark Results [HICON]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    HICON
    HICON
    85924803 4577066 Live/Registered
    McAllister, Sean
    2013-05-07
    HICON
    HICON
    85853144 4520164 Live/Registered
    HICON GROUP CO., LTD.
    2013-02-19
    HICON
    HICON
    79371227 not registered Live/Pending
    Johnson Matthey Public Limited Company
    2023-05-03
    HICON
    HICON
    79270411 not registered Live/Pending
    HICON GROUP CO., LTD
    2019-07-23
    HICON
    HICON
    79053310 not registered Dead/Abandoned
    NINGBO HICON GROUP CO., LTD
    2007-09-27
    HICON
    HICON
    79011076 3202266 Dead/Cancelled
    NINGBO HICON GROUP CO., LTD
    2005-03-25
    HICON
    HICON
    77682133 3815354 Live/Registered
    Dong Weon HWANG
    2009-03-03
    HICON
    HICON
    76589735 3707249 Live/Registered
    JUBILANT DRAXIMAGE INC.
    2004-04-02
    HICON
    HICON
    76109451 2471735 Live/Registered
    Hicon Inc.
    2000-08-15
    HICON
    HICON
    74521976 1908327 Live/Registered
    EBNER INDUSTRIEOFENBAU GESELLSCHAFT m.b.H
    1994-05-05
    HICON
    HICON
    74417486 not registered Dead/Abandoned
    Johnson Matthey Inc.
    1993-07-27
    HICON
    HICON
    73516183 1350468 Dead/Cancelled
    ROYAL OPTICAL COMPANY, INC.
    1985-01-04
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.